Compound Profiles

Derived from a protective protein found in gastric juice. Studied extensively in animal models for its effects on tissue healing and gastrointestinal protection.

TB-500 is a synthetic version of a naturally occurring peptide. Research focuses on its role in actin dynamics and cell migration relevant to wound healing.

A naturally occurring copper-binding tripeptide. Studied for its role in wound healing, collagen and elastin synthesis, and anti-inflammatory activity in tissue models.

A C-terminal fragment of alpha-MSH. Studied for anti-inflammatory properties in gut and skin models, particularly in the context of inflammatory bowel disease research.

A tight junction regulator studied for its ability to reduce intestinal permeability. Has been evaluated in clinical trials for celiac disease.

A growth hormone-releasing hormone analogue with extended half-life. Studied for its effects on GH secretion and IGF-1 levels.

A selective growth hormone secretagogue. Studied for selectivity relative to other GH-releasing peptides, with minimal effect on cortisol or prolactin in preclinical models.

A synthetic hexapeptide that stimulates GH release via the ghrelin receptor. One of the most studied GHRP compounds, with documented effects on GH pulse amplitude.

One of the original synthetic GH secretagogues. Studied for GH release and appetite stimulation via ghrelin receptor agonism. Also investigated for cardioprotective properties.

A potent synthetic GH secretagogue. Studied for cardiovascular protective effects independent of GH release, including research on cardiac function in animal models.

A synthetic fragment of endogenous GHRH. Previously FDA-approved as a diagnostic agent. Research has examined its role in GH secretion and age-related GH decline.

An FDA-approved GHRH analogue for HIV-associated lipodystrophy. RUO research compounds are distinct from the approved pharmaceutical product.

A non-peptide orally active GH secretagogue. Studied for sustained GH and IGF-1 elevation. Technically a small molecule, not a peptide, but commonly catalogued alongside GH-axis peptides.

An FDA-approved drug for hypoactive sexual desire disorder. RUO research compounds are distinct from the approved pharmaceutical product.

A cyclic melanocortin analogue studied for its effects on MC1R and MC4R. Research has examined pigmentation, appetite suppression, and sexual function in animal models.

An FDA-approved MC1R agonist for erythropoietic protoporphyria. A potent synthetic analogue of alpha-MSH with extended receptor binding.

A synthetic analogue of the immunomodulatory peptide tuftsin. Studied in anxiety and cognitive models, with a body of research originating from Russian academic institutions.

An ACTH-derived peptide studied for neuroprotective properties in animal models. Research has examined BDNF upregulation and cognitive performance in rodent studies.

A hepatocyte growth factor (HGF) amplifier studied for cognitive effects in animal models. Research has examined synaptogenesis and memory performance in rodent Alzheimer's models.

A brain-derived peptide preparation studied for neuroprotective and neurotrophic effects. Approved in several European and Asian countries; subject of ongoing clinical research.

Derived from activity-dependent neuroprotective protein (ADNP). Studied for neuroprotective effects in tau-related pathology and cognitive models.

A peptide derived from ciliary neurotrophic factor (CNTF). Studied for its ability to increase BDNF and promote neurogenesis in animal models without the side effects associated with full CNTF.

A tetrapeptide studied in the context of telomerase activity and aging biology. Research originates primarily from the St. Petersburg Institute of Bioregulation and Gerontology.

A mitochondria-derived peptide with cytoprotective properties. Studied for its role in inhibiting apoptosis and its potential relevance to age-related neurodegeneration.

A mitochondria-derived peptide that translocates to the nucleus under metabolic stress. Studied for its role in metabolic homeostasis, insulin sensitivity, and longevity pathways.

A mitochondria-targeted peptide that concentrates in the inner mitochondrial membrane. Studied for cardioprotective and renoprotective effects in ischemia-reperfusion models.

A thymic peptide that modulates T-cell maturation and immune response. Approved in over 35 countries for hepatitis B, hepatitis C, and as an adjunct in cancer therapy.

The endogenous form of the peptide that TB-500 is derived from. Studied for its role in actin dynamics, wound healing, and cardiac tissue repair in preclinical models.

The only known human cathelicidin antimicrobial peptide. Studied for broad-spectrum antimicrobial activity, immunomodulation, and wound healing in preclinical and clinical contexts.

A zinc-dependent thymic hormone involved in T-cell differentiation. Studied in the context of immune aging and thymic involution.

An FDA-approved GLP-1 receptor agonist for type 2 diabetes and obesity. RUO research compounds are distinct from the approved pharmaceutical product.

An FDA-approved dual GIP and GLP-1 receptor agonist. RUO research compounds are distinct from the approved pharmaceutical product.

A modified fragment of human growth hormone (hGH 176-191). Studied for lipolytic activity in adipose tissue models without the growth-promoting effects of full hGH.

An endogenous nonapeptide hormone. Studied for roles in social bonding, appetite regulation, and metabolic function beyond its well-established obstetric applications.

An endogenous peptide of the renin-angiotensin system that acts as a counter-regulatory axis to angiotensin II. Studied for vasodilatory, anti-fibrotic, and cardioprotective properties.

An endogenous cardiac hormone used as a biomarker for heart failure. The recombinant form (nesiritide) is FDA-approved for acute decompensated heart failure.

An FDA-approved synthetic analogue of a conotoxin from the cone snail Conus magus. Approved for severe chronic pain. Blocks N-type voltage-gated calcium channels.

An endogenous neuropeptide and neurotransmitter involved in pain signaling. Widely used as a research tool to study nociception, neurogenic inflammation, and NK1 receptor pharmacology.

An endogenous antimicrobial peptide expressed in epithelial tissues. Studied for its role in innate immune defense against bacteria, fungi, and viruses.

An antimicrobial peptide isolated from African clawed frog skin. Widely used as a model compound to study membrane-disrupting antimicrobial mechanisms.

An FDA-approved anabolic agent for osteoporosis. The active fragment of parathyroid hormone. RUO research compounds are distinct from the approved pharmaceutical product.

Enzymatically hydrolyzed collagen fragments. Studied for effects on joint cartilage, bone density, and skin elasticity in both preclinical and clinical settings.

Peptide fragments derived from or mimicking VEGF. Used as research tools to study angiogenesis, vascular permeability, and endothelial cell biology.

An endogenous inhibitor of angiogenesis derived from collagen XVIII. Studied extensively in tumor biology as a potential anti-angiogenic agent.

The endogenous ligand for the GH secretagogue receptor. Studied for its role in appetite stimulation, GH release, and gut motility. The acylated form is the active species.

An endogenous neuropeptide with broad biological activity. Studied for roles in gut motility, vasodilation, bronchodilation, and immune modulation.